First Turn Management’s Cytokinetics CYTK Stock Holding History

First Turn Management's CYTK Position: Q1 2026 in Review

First Turn Management reduced its Cytokinetics (CYTK) stake by 13% in Q1 2026, selling an estimated $2.67M and leaving 283,700 shares worth $18.7M. The position accounts for 2.09% of the portfolio, ranked #19.

First Turn Management first reported a position in CYTK in Q4 2023 and has held it in 7 quarters since. The position peaked at $67.4M in Q4 2023. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

• First Turn Management held 283,700 shares of Cytokinetics worth $18.7M as of Q1 2026.
• First Turn Management sold 41,968 Cytokinetics shares in Q1 2026, an estimated $2.67M.
• Cytokinetics made up 2.09% of First Turn Management's portfolio in Q1 2026, its #19 holding.
• First Turn Management first reported a position in Cytokinetics in Q4 2023 and has held it in 7 quarters since.
• First Turn Management's Cytokinetics position peaked at $67.4M in Q4 2023.
• 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on First Turn Management's 13F filing for Q1 2026, filed 15 May 2026.